Navigation Links
AMA Rejects PBS 'Measure and Share' Proposals

The AMA Federal Council has rejected outright Pharmaceutical Benefits Scheme (PBS) 'measure and share' proposals, which are currently being pushed by some medical groups. //

AMA President, Dr Mukesh Haikerwal, said today that any PBS savings derived from changed prescribing patterns must be re-invested back into the PBS.

'Evidence-based prescribing information and other education strategies, including details of comparative prescribing patterns, contribute to improvements in the quality use of medicines,' Dr Haikerwal said.

The AMA supports the education activities of the National Prescribing Service, particularly at the local level, which include:

  • The provision of independent, evidence-based information regarding best practice prescribing and use of medicines


  • The development and implementation of opportunities for GPs to participate in peer review of prescribing


  • The development and dissemination of public education regarding quality use of medicines


  • Dr Haikerwal said that rather than pursuing 'measure and share' programs, the AMA wants the Government to boost National Prescribing Service resources and funding to allow them to broaden the range and reach of their services.

    'The AMA emphasises that any PBS savings derived from Quality Use of Medicines activities must be retained within the PBS to benefit all Australians.

    'There should never be any doubt that prescribing is best practice and patient-centred, and there are no ulterior motives attached to treatments prescribed,' Dr Haikerwal said.
    '"/>




    Page: 1

    Related medicine news :

    1. Games Event Rejects Prior Transplant Patient
    2. Court Rejects Case of Negligence by Disabled Children against the Doctors
    3. Apex Consumer Court Rejects Rs 143 Cr Medical Negligence Claim
    4. Spanish Fashion Show Rejects Five Models as too Thin
    5. Single Women and Lesbians To Enjoy Full Rights in Donor Child Proposals
    6. Tuberculosis Experts Outline Proposals to Speed Up Drug Development
    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
    (Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
    (Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
    (Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
    Breaking Medicine News(10 mins):
    (Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
    (Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
    (Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
    Breaking Medicine Technology: